Pharmacology and Pharmaceutical Sciences articles for Canada

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 82

Article ‘Count’ for Pharmacology and Pharmaceutical Sciences.

Journal Count Share
1 0.03
Jigsaw Puzzle-Designed Polyphenol-Macromolecular Supramolecular Networks for Noninvasive Therapy of Deep-Tissue Oral Disease 0.03
3 2.30
In Vivo Negligible Depletion SPME for the Determination of Free and Total Concentrations of Anandamide and 2-Arachidonoylglycerol in the Brain of a Parkinson’s Disease Rat Model 0.30
Complete and Rapid NMR Characterization of Therapeutic Monoclonal Antibodies via Differential Labeling of Fab Fragments in Escherichia coli 1.00
A Potential Mercury Polymer Mass Tag Probe for Mass Cytometry 1.00
2 0.78
Mitigating Molecular Aggregation in Drug Discovery With Predictive Insights From Explainable AI 0.60
Spherical Nucleic Acids‐Directed Cryosynthesis of Manganese Nanoagents for Tumor Imaging and Therapy 0.18
1 0.27
Multicenter Trial of the Emergency Department Trigger Tool 0.27
3 0.96
Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes. 0.05
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study. 0.80
Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide. 0.11
1 0.06
Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study 0.06
2 0.47
Glucagon‐like peptide‐1 receptor agonist therapy is associated with improvement in psoriatic arthritis‐related and metabolic outcomes: A retrospective analysis of two cohorts 0.29
Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step toward Precision Drug Monitoring 0.19
1 1.00
LUMI-lab: A foundation model-driven autonomous platform enabling discovery of ionizable lipid designs for mRNA delivery 1.00
1 0.80
The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors 0.80
4 3.08
Phospholipid asymmetry in biomimetic vesicles alters membrane permeability 1.00
Rotisserie-like motion enables guest transport in a nonporous organic crystal involving a diboron host 0.08
Organocatalytic peptide coacervates as microreactors for aqueous aldol additions 1.00
A two-step continuous flow synthesis of multi-tail ionizable lipids 1.00
1 1.00
Young chronic e-cigarette users display cardiopulmonary abnormalities during exercise and blunted recruitment of pulmonary diffusing capacity 1.00
1 0.03
A Nationwide Factorial Randomized Trial of Electronic Nudges to Patients with Chronic Kidney Disease and Their General Practices for Increasing Guideline-Directed Medical Therapy: The NUDGE-CKD Trial. 0.03
3 0.15
Direct Oral Challenge for Penicillin Allergy: A Hospital Implementation Evaluation Via the International Network of Antibiotic Allergy Nations (iNAAN) Study 0.01
Direct Oral Challenge for Penicillin Allergy: The International Network of Antibiotic Allergy Nations (iNAAN) Study 0.01
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials 0.14
2 1.03
Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP). 0.10
Methylene Blue Administration in Septic Shock: A Retrospective Cohort Study. 0.93
2 0.75
Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes. 0.72
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study. 0.03
3 2.05
Predictors, Sources, and Health Risks of Environmental Antibiotic Exposure in Chinese Pregnant Women 0.05
Brain concentrations of flame retardants and trace elements related to habitat use and brain measures in an urban-adapted gull 1.00
Maternal and paternal dietary arsenic exposure impairs reproduction and development in zebrafish offspring: the role of HPG axis dysregulation and altered DNA methylation 1.00
9 5.52
Association between gestational and childhood exposures to organophosphate esters and social skill, problem behavior among adolescents 0.08
Identifying associations and key early life exposure windows for organophosphate esters and adolescent brain morphometry in the HOME study 0.06
Prenatal and early life exposure to organophosphate esters and intellectual quotient at age 3, in the SEPAGES cohort 0.15
Chronic exposure to selenium through a natural diet (Lumbriculus variegatus) resulted in endocrine disruption, and reproductive impairment in zebrafish (Danio rerio) 0.80
Urinary arsenic levels and risk of breast cancer among women in the Canadian health measures survey: a population-based prospective study 0.88
Non-invasive Welding Fumes Exposure Assessment using Exhaled Breath Condensate 1.00
Maternal exposure to trace elements and perfluoroalkyl acids and their associations with alterations of the hypothalamic-pituitary-adrenal axis 0.89
Descriptive analysis of whole blood concentrations of toxic, essential, and trace elements in adult females from the MIREC-ENDO study 1.00
Associations between prenatal exposure to a mixture of lead, mercury and polychlorinated biphenyls and executive function in Inuit adolescents 0.67
1 0.06
Acrylamide Exposure and Type 2 Diabetes in a Prospective Cohort Study of Chinese Adults: Association, Mediation, and Gene–Environment Interaction 0.06
1 0.92
Impact of gender-affirming hormone therapy on spermatogenesis: analysis of testicular histological specimens 0.92
1 0.14
Planar and Nonplanar Polymorphic Forms of Ni(II)-Porphyrin: Photophysical, Photocatalysis, and DFT Study 0.14
1 1.00
Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin 1.00
3 2.38
Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial 0.50
<atl>Cefazolin inoculum effect and cefazolin microbiological treatment failure in serious methicillin-susceptible iStaphylococcus aureus/i infections: A multi-center retrospective cohort study</atl> 1.00
Fetal Defects in Mice Treated with Integrase Strand Transfer Inhibitors: Comparison of Dolutegravir, Raltegravir, Bictegravir and Cabotegravir 0.88
1 1.00
Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet‐induced obesity 1.00
1 1.00
An Artificial Intelligence and Machine Learning model for Personalized Prediction of Long-term Mitral Valve Repair Durability 1.00
3 2.10
Cancer Cells Degrade the Nanoparticle Protein Corona for Biosynthesis 0.69
An Expedient Synthesis of the Antimitotic Natural Products Sarcodictyin and Eleutherobin, and Carbohydrate Analogues 1.00
The Binding Affinities of Serum Proteins to Nanoparticles 0.40
2 1.03
Enhancing Medication Adherence in Older Adults: A Systematic Review of Evidence‐Based Strategies 0.03
Association of Inpatient Prescribing of First‐Generation Antihistamines With Delirium in Older Adults: A Cross‐Sectional Study 1.00
2 1.14
Molecular Dynamics Study on the Temperature Response of a Chitosan-Based Graft Polymer with Different Grafting Densities of Oligo(ethylene glycol) Methacrylate Side Chains 0.14
Facile Synthesis of Trialkylamine Oxide-Modified Platinum Polymer Probes for Mass Cytometry 1.00
1 0.10
Pharmacogenomics of antiepileptic drug mood stabilizer treatment response in bipolar disorder: A MoStGen Consortium study 0.10
3 0.72
Language model-guided anticipation and discovery of mammalian metabolites 0.44
Atomically accurate de novo design of antibodies with RFdiffusion 0.06
Identification of medication–microbiome interactions that affect gut infection 0.22
1 0.10
Deep-learning-based virtual screening of antibacterial compounds 0.10
1 0.96
Unlocking chemical diversity in aptamers with DNA orthogonal barcodes 0.96
5 2.02
Disentangled autoencoding equivariant diffusion model for controlled generation of 3D molecules 0.20
Reliable repurposing of the antibody interactome inside the cell 0.07
A resource to empirically establish drug exposure records directly from untargeted metabolomics data 0.03
Systematic metaproteomics mapping reveals functional and ecological landscapes of Ex vivo human gut microbiota responses to therapeutic drugs 0.72
Characterization of PROTAC specificity and endogenous protein interactomes using ProtacID 1.00
1 0.02
Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals 0.02
1 0.73
Runx1 transcription factor modulates opioid analgesia and withdrawal in humans and rodents 0.73
2 0.29
B(C6F5)3-Catalyzed Dearomative [2π+2σ] Cycloaddition of 1-Naphthols with Bicyclo[1.1.0]butanes 0.17
Metal-Free, Photoinduced On-DNA Synthesis of β-Hydroxy Sulfides 0.13
1 0.14
Genetic variation in the FMO and GSTO gene clusters impacts arsenic metabolism in humans. 0.14
3 0.94
Mechanical performance of hybrid polymer–lipid vesicles with leaflet asymmetry engineered using microfluidics 0.05
Cannabis produces acute hyperphagia in humans and rodents via increased reward valuation for, and motivation to, acquire food 0.67
Manifold-constrained nucleus-level denoising diffusion model for structure-based drug design 0.22
1 0.60
A unified platform for nucleoside analog synthesis 0.60
3 1.14
In vivo functional profiling and structural characterization of the human GLP1R A316T variant 0.02
α cells use both PC1/3 and PC2 to process proglucagon peptides and control insulin secretion 0.14
Machine learning-assisted exploration of multidrug-drug administration regimens for organoid arrays 0.98
1 0.09
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials 0.09
1 0.03
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study 0.03
1 0.13
Graph neural network-based prediction and interpretation of Daphnia toxicity using distinct scale molecular representations 0.13

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.